Abstract
Traumatic brain injury (TBI) is a devastating disease, predominantely affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.
Keywords: Pharmacology, Traumatic Brain Injury
Current Pharmaceutical Design
Title: Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Volume: 12 Issue: 13
Author(s): Niklas Marklund, Asha Bakshi, Deborah J. Castelbuono, Valeria Conte and Tracy K. McIntosh
Affiliation:
Keywords: Pharmacology, Traumatic Brain Injury
Abstract: Traumatic brain injury (TBI) is a devastating disease, predominantely affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.
Export Options
About this article
Cite this article as:
Marklund Niklas, Bakshi Asha, Castelbuono J. Deborah, Conte Valeria and McIntosh K. Tracy, Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury, Current Pharmaceutical Design 2006; 12 (13) . https://dx.doi.org/10.2174/138161206776843340
DOI https://dx.doi.org/10.2174/138161206776843340 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters Clinical Case of Organic Pseudopsychopathic Disorder in a Teenager in Terms of Differential Diagnostics with Childhood Schizophrenia
Current Psychiatry Research and Reviews Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Toxicogenomics to Evaluate Endocrine Disrupting Effects of Environmental Chemicals Using the Zebrafish Model
Current Genomics Brain Structural Effects of Antidepressant Treatment in Major Depression
Current Neuropharmacology Xanthan Gum Coated Mucoadhesive Liposomes for Efficient Nose to Brain Delivery of Curcumin
Drug Delivery Letters Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Epigenetic Changes in the Methylation Patterns of KCNQ1 and WT1 after a Weight Loss Intervention Program in Obese Stroke Patients
Current Neurovascular Research A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Neurohypophyseal Dysfunction During Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option
Current Topics in Medicinal Chemistry Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Uric Acid and Oxidative Stress
Current Pharmaceutical Design Anti-Inflammatory Activity of Novel 12-N-methylcytisine Derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction
Current Hypertension Reviews Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research